The retiring Paul Perreault is to be replaced by another Paul as chief executive and managing director of Australian biotech CSL Limited (ASX: CSL).
Mr Perreault is to step down in early March after 10 years in the role and more than 25 years with the Melbourne-based company. He will remain a strategic adviser to assist in an orderly transition until September.
CSL’s current chief operating officer (COO) Paul McKenzie will take over. He has more than 30 years of leadership experience in the global biotech industry, including leading complex organizations through growth and transformation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze